Verici Dx reveals positive validation study results
Platform Biotec stocks come in various shapes & sizes. However, one important trait is that they have the potential to generate enormous shareholder value from a common DNA.
It’s no different for Verici Dx - a next generation, immuno-diagnostics firm, focusing initially on kidney transplants.
Today the company said that following the publication of industry leading results (re 60% PPV, Positive Predictive Value) for its 1st break-through Tuteva test in June.
Its 2nd Clarava (a pre-transplant blood-based prognostic) had also passed an extensive ‘real world’ validation study with flying colours.
Meaning that it too was “an effective tool to identify patients likely to experience a future transplant rejection”.
Which also could “have wide-ranging implications regarding patient treatment plans (eg adjusting immuno-suppressant & steroid dosage) ahead of transplant, post-operatively and monitoring response”.
Before commercial launch though, some additional clinical data would need be collected over the next 6 months (albeit piggy-backing on already planned Protega work) in order to further enrich the results, expand Clarava’s usage and broaden the addressable market.
Currently there is no competitor product either.
Therefore, each of these 2 tests on their own offer significant value catalysts. But taken together, I believe they validate the applicability and efficacy of VRCI’s proprietary AI-enabled & RNA sequenced, immuno-diagnostics platform.
Whereby going forward this same core science, should be able to provide the genesis for multiple new diagnostics & related services.
CEO Sara Barrington commenting: “This new validating data demonstrates that Clarava can have a significant impact for transplant clinicians understanding of which patients could experience early acute rejection, pre-surgery. As a result, clinicians can make better decisions in advance that can help drive better outcomes post-transplant.”
In summery not only offering doctors a step change in medical science, but also generating a series of potential high margin, new product launches for Verici Dx.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.